|
AstraZeneca PLC - Cambridge-based pharmaceutical maker - Says Forxiga drug meets primary endpoints in T2NOW phase three trial and shows ‘clinically meaningful’ improvements in the glycaemic control among type two diabetes patients between the ages of 10 and 17. Adds safety results in patient cohort were consistent with those in adults with type two diabetes. Executive vice president for AstraZeneca’s BioPharmaceuticals business unit, Ruud Dobber, says: ‘Today’s results from one of the largest studies into children suffering from type [two] diabetes, offers hope. Despite the growing global burden of type [two] diabetes among children and adolescents, the treatment options available are currently limited. It is well documented that some patients find injectable therapies challenging, making the need for effective oral treatment alternatives paramount.’ Current stock price: 10,874.00 pence, down 0.3% 12-month change: up 9.2% Copyright 2023 Alliance News Ltd. All Rights Reserved.
|
